Regeneron Pharmaceuticals Inc vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while iShares 1 3 Year Treasury Bond ETF trades at $81.66. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while iShares 1 3 Year Treasury Bond ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| REGN | SHY | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | Fixed Income |
52-Week High | $852.03 | $83.18 |
52-Week Low | $555.51 | $81.59 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
SHY is currently trading at $81.66, showing minimal daily movement with a slight decline of 0.04%. The technical picture appears bearish with moving averages signaling caution, though oscillators suggest some buying opportunity. Recent corporate actions include consistent dividend payments scheduled through mid-2026, providing income stability for shareholders amid market volatility.
The outlook for SHY reflects mixed signals with technical indicators showing bearish momentum but potential oversold conditions. Investment opportunities include dividend income stability, while risks center on broader bond market volatility and interest rate sensitivity. The stock faces headwinds from rising Treasury yields and inflation concerns that could pressure fixed-income investments.
Trailing returns across standard periods
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →